BioCentury | Jul 9, 2012
Strategy

Triple play in diabetes

...Mkt Bydureon exenatide [Alkermes plc (NASDAQ:ALKS)] Once-weekly long-acting release (LAR) formulation of synthetic exendin-4 Mkt Symlin/SymlinPen...
BioCentury | Apr 28, 2008
Company News

Amylin sales and marketing update

...Amylin launched its SymlinPen 120 and SymlinPen 60 pen-injector devices for administration of Symlin pramlintide. The...
BioCentury | Oct 22, 2007
Clinical News

SymlinPen regulatory update

...FDA approved an sNDA from AMLN for the SymlinPen 120 and SymlinPen 60 pen-injector devices for...
...the pens to be available by December. Amylin Pharmaceuticals Inc. (AMLN), San Diego, Calif. Product: SymlinPen...
BioCentury | Oct 8, 2007
Finance

Ebb & Flow

...Amylin (AMLN) added $0.81 to $50.81 last week after FDA approved the SymlinPen 120 and SymlinPen...
BioCentury | Oct 2, 2007
Company News

FDA approves SymlinPen

...FDA approved the SymlinPen 120 and SymlinPen 60 pen-injector devices from Amylin (AMLN) for administration of...
Items per page:
1 - 5 of 5